Ainos Q3 2023 revenue drops 98.6% to $24.5K; net loss narrows to $3.0M

Ainos, Inc.

2024-Q3 EPS reported -$1.95 revenue$102,208

Revenue fell to $24,489 from $1,757,774 in Q3 2022 due to COVID-19 test kit demand decline.
Gross profit turned negative ($63,384) vs positive $581,742 YoY on lower sales and inventory loss.
Net loss narrowed to $2.97M from $7.82M YoY, helped by lower operating expenses.
Cash and equivalents $2.37M as of Sept 30, 2023; company secured $3M of planned $10M private placement.
VELDONA Pet launched in Taiwan (300k units shipped); FDA orphan drug designation for VELDONA for oral warts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Ainos, Inc. reported third quarter ended September 30, 2023 results: revenue US$24,489, net income US$2,975,846.

Period: third quarter ended September 30, 2023
Revenue: US$24,489
Net income: US$2,975,846
Result: reported results

Exact text from the filing

Revenues were US$24,489 in the third quarter of 2023, compared to US$1,757,774 in the same period of 2022

View on SEC.gov

Browse all earnings releases →

Ainos, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-014166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.